Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

The immunomodulatory agent, lenalidomide, is a structural analogue of thalidomide approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS) and multiple myeloma (MM). This agent is also currently under active investigation for the treatment of chronic lympho...

Full description

Saved in:
Bibliographic Details
Main Authors: Jessica M. McDaniel, Javier Pinilla-Ibarz, P. K. Epling-Burnette
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Advances in Hematology
Online Access:http://dx.doi.org/10.1155/2012/513702
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items